Aclaris Therapeutics, Inc.
ACRS · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $174 | $187 | $236 |
| - Cash | $25 | $25 | $30 | $25 |
| + Debt | $2 | $2 | $2 | $3 |
| Enterprise Value | – | $151 | $159 | $214 |
| Revenue | $3 | $2 | $1 | $9 |
| % Growth | 85.6% | 22.1% | -84.2% | – |
| Gross Profit | $3 | -$0 | $1 | -$0 |
| % Margin | 83.7% | -4.1% | 65.2% | -1% |
| EBITDA | -$14 | -$17 | -$18 | -$14 |
| % Margin | -436.6% | -945.1% | -1,213.5% | -151.2% |
| Net Income | -$15 | -$15 | -$15 | -$97 |
| % Margin | -443% | -868.3% | -1,036.8% | -1,048.2% |
| EPS Diluted | -0.12 | -0.13 | -0.12 | -1.01 |
| % Growth | 7.7% | -8.3% | 88.1% | – |
| Operating Cash Flow | -$11 | -$10 | -$13 | -$9 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$36 |
| Free Cash Flow | -$11 | -$10 | -$13 | -$45 |